Table 3 Cognitive assessments

From: A Phase IIa clinical trial to evaluate the effects of anti-retroviral therapy in Alzheimer’s disease (ART-AD)

DOMAIN

TEST

BASELINE MEDIAN (IQR)

POST-TREATMENT MEDIAN (IQR)

P-value

Global

MMSE

27 (25, 29)

25 (23, 28)

0.06

AD composite

PACC-5 (Z-score)

−1.59 (−2, −0.59)

−1.59 (−2, −1.2)

0.07

Attention & working memory

Digits Forward

6 (5, 7)

6 (5, 7)

0.8

Digits Backward

4 (4, 5)

4 (4, 5)

0.2

Verbal list learning

HVLT Learning

15 (14, 18)

16 (13, 21)

>0.9

HVLT Recall

0 (0, 4)

0 (0, 4)

>0.9

HVLT Disc

6 (2, 9)

6 (3, 9)

>0.9

Visual learning

BVMT Learning

9 (5, 11)

8.5 (6, 10)

0.8

BVMT Recall

2 (0, 3)

2 (1, 3)

0.8

BVMT Disc

4 (3, 5)

4 (3, 5)

0.4

Story memory

Logical Memory I

22 (18, 25)

18 (16, 24)

0.3

Logical Memory II

6 (2, 9)

4 (0, 8)

0.8

Logical Memory Rec

16 (14, 18)

16 (14, 16)

0.3

Episodic memory

FCSRT Delay Free

2 (0, 6)

2 (0, 6)

0.7

FCSRT Delay Cued

9 (6, 10)

10 (8, 11)

0.8

Naming

BNT

29 (28, 29)

29 (27, 30)

0.4

Verbal fluency

Animal Naming

14 (13, 17)

15 (13, 17)

0.4

Supermarket

20 (16, 26)

19 (16, 22)

0.11

S Words

11 (10, 14)

11 (10, 13)

0.7

P Words

12 (9, 13)

12 (10, 14)

0.08

Executive functioning

Trails A Time

44 (38, 64)

49 (32, 56)

0.7

Trails B Time

114 (94, 205)

105 (92, 280)

0.4

Digit-Symbol Coding

46 (34, 49)

39 (37, 47)

>0.9

  1. IQR interquartile range. P value is based on Wilcoxon signed rank test with continuity correction. N = 12.